Evidence map›Paper›PMID 41125158›Full record

ArticleJournal of substance use and addiction treatment2025

Impact of a brief personally tailored opioid-overdose and medication for opioid use disorder education intervention on naloxone acceptance in peripartum individuals: A secondary exploratory analysis.

Michelle R Lofwall, Frankie Kropp, Jasmin Charles, Gerald Cochran, Antoine Douaihy, Mary Edwards, Daniel Lewis, Carmen Rosa, Jessica L Young, T John Winhusen

Abstract read
In one paragraph

Article in Journal of substance use and addiction treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Michelle R LofwallUniversity of Kentucky College of Medicine, Departments of Behavioral Science and Psychiatry, Center on Drug and Alcohol Research, 845 Angliana Avenue, Lexington, KY, 40508, United States of America. Electronic address: michelle.lofwall@uky.edu.
Frankie KroppUniversity of Cincinnati College of Medicine, Department of Psychiatry and Behavioral Neuroscience, Center for Addiction Research, 3131 Harvey Avenue, Suite 104, Cincinnati, OH 45229, United States of America. Electronic address: kroppfb@ucmail.uc.edu.
Jasmin CharlesUniversity of Utah, Department of OBGYN, SUPeRAD clinic, University Hospitals and Clinics, 50 N. Medical Drive, Salt Lake City, UT, 84132, United States of America. Electronic address: jasmin.charles@hsc.utah.edu.
Gerald CochranUniversity of Utah, Department of Internal Medicine, Division of Epidemiology, 295 Chipeta Way, Salt Lake City, UT, 84108, United States of America. Electronic address: jerry.cochran@hsc.utah.edu.
Antoine DouaihyUniversity of Pittsburgh School of Medicine, Department of Psychiatry; Pregnancy Recovery Center/Magee Women's Hospital, 300 Halket Street, Pittsburgh, PA, 15213, United States of America. Electronic address: douaihya@upmc.edu.
Mary EdwardsMarshall University Joan C. Edwards School of Medicine, Department of Family and Community Health, 1600 Medical Center Drive, Huntington, WV, 25701, United States of America.
Daniel LewisUniversity of Cincinnati College of Medicine, Department of Psychiatry and Behavioral Neuroscience, Center for Addiction Research, 3131 Harvey Avenue, Suite 104, Cincinnati, OH 45229, United States of America. Electronic address: lewisdw@ucmail.uc.edu.
Carmen RosaNational Institute on Drug Abuse, Center for the Clinical Trials Network, C/O NIH Mail Center, NIDA 3WFN MSC 6022, 16071 Industrial Drive - Dock 11, Gathersburg, MD, 20892, United States of America.
Jessica L YoungVanderbilt University Medical Center, Department of Obstetrics and Gynecology, Nashville, Vanderbilt Center for Women's Health, One Hundred Oaks, 719 Thompson Lane, Nashville, TN, 37204, United States of America. Electronic address: jessica.l.young@vumc.org.
T John WinhusenUniversity of Cincinnati College of Medicine, Department of Psychiatry and Behavioral Neuroscience, Center for Addiction Research, 3131 Harvey Avenue, Suite 104, Cincinnati, OH 45229, United States of America. Electronic address: winhust@ucmail.edu.

Funding

The Florida Node Alliance of the National Drug Abuse Treatment Clinical Trials NetworkUG1DA013720 · NIDA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Daniel J Feaster, Viviana Elizabeth Horigian · 2015 to 2026
$50.6M
The Ohio Valley Node of the Clinical Trials Network (CTN-0153)UG1DA013732 · NIDA · UNIVERSITY OF CINCINNATI · PI T John WINHUSEN · 2015 to 2026
$42.5M
Southern Consortium Node of the Clinical Trials Network (Varenicline)UG1DA013727 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI KATHLEEN T. BRADY, Kelly S. Barth · 2015 to 2026
$24.8M
Greater Intermountain Node (CTN-0151)UG1DA049444 · NIDA · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Gerald T. Cochran, Gerald T. Cochran · 2019 to 2026
$16.8M
Project-008UG1DA049436 · NIDA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Jane M. Liebschutz, Erin L Winstanley · 2019 to 2026
$10.5M
NIDA NIH HHS UG1 DA013720NIDA NIH HHS UG1 DA013727NIDA NIH HHS UG1 DA013732NIDA NIH HHS UG1 DA049436NIDA NIH HHS UG1 DA049444
6 · The paper itself

Abstract

objectivesDespite drug overdose deaths increasing among peripartum persons, little is known about how to increase naloxone acceptance in this population. This study evaluated the effect of a brief 15-min computer facilitated personally-Tailored Opioid- overdose and Medication for opioid use disorder (MOUD) Educational intervention (TOME) on naloxone uptake and compared participant characteristics based on naloxone acceptance.

methodsThis secondary analysis is from an outpatient randomized multisite trial with peripartum individuals receiving MOUD treatment. Participants were randomized to TOME or control. TOME participants met 1:1 with research staff to review a printout of missed pre-test opioid overdose and MOUD knowledge questions that explained the correct answer. Control participants received educational materials from the Substance Abuse and Mental Health Services Administration. Baseline demographics, treatment characteristics, opioid overdose and MOUD knowledge, and self-report MOUD stigma ratings were compared between participants who accepted versus declined free study-provided naloxone because they already had it or for other reasons. The intervention's effect on naloxone acceptance was evaluated after delivery of TOME or control among those accepting versus those declining naloxone for other reasons.

resultsOf 111 participants, 90 accepted naloxone, 14 declined due to already having naloxone, and seven declined for other reasons (e.g., not affiliating with people who would need it, not wanting it in their house, allergy), These three groups significantly differed on past stigma from family (p = 0.007) and employers (p = 0.013) whereby participants declining naloxone due to already having it had the lowest stigma. Those accepting naloxone (n = 90) were nearly evenly split between TOME (n = 48) and control (n = 42). Six of the seven declining naloxone for other reasons were control participants. Among the 97 accepting naloxone or declining it for other reasons, TOME trended toward increasing naloxone acceptance (OR: 6.857, CI: 0.793, 59.291, Fisher Exact test p = 0.0592). There was a higher percentage of correct MOUD answers in the 90 accepting naloxone (66.8 %) vs. the 7 declining for other reasons (55.7 %; p = 0.0471).

conclusionsThese preliminary results suggest the need for further work to determine if educational interventions can enhance naloxone acceptance and suggest that stigma and medication treatment knowledge may be important factors influencing naloxone acceptance.

Indexed as

educationnaloxoneopioid use disorderoverdoseperipartum

Identifiers

PMID41125158
PMCPMC12628068

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.